1-8 of 8
D Shah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P4-09-08: Outcomes after Autologous Breast Reconstruction for Triple-Negative Breast Cancer among Black and White Patients

Free
Mattia Mahmoud, Dustin Crystal, Sarah Barnett, Stephany Perez-Rojas, Payal D Shah, Neil K. Taunk, Robyn Broach, Said C. Azoury, Oluwadamilola "Lola" Fayanju
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P4-09-08.
https://doi.org/10.1158/1557-3265.SABCS24-P4-09-08
Published: 13 June 2025
View article titled, Abstract P4-09-08: Outcomes after Autologous Breast Reconstruction for Triple-Negative Breast Cancer among Black and White Patients
Journal Articles

Abstract P2-07-04: [18F]FluorThanatrace PET imaging correlates with response to PARP inhibitors in breast cancer: a pilot study

Free
Austin R. Pantel, Kara Maxwell, Anthony Young, Daniel A. Pryma, Michael D. Farwell, Fang Liu, Quy Cao, Sophia R. O'Brien, Amy S. Clark, Payal D. Shah, Elizabeth S. McDonald
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P2-07-04.
https://doi.org/10.1158/1557-3265.SABCS24-P2-07-04
Published: 13 June 2025
View article titled, Abstract P2-07-04: [18F]FluorThanatrace PET imaging correlates with response to PARP inhibitors in breast cancer: a pilot study
Journal Articles

C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Available to Purchase
Stephanie L. Wethington, Payal D. Shah, Lainie Martin, Janos L. Tanyi, Nawar Latif, Mark Morgan, Drew A. Torigian, Diego Rodriguez, Simon A. Smith, Emma Dean, Susan M. Domchek, Ronny Drapkin, Ie-Ming Shih, Eric J. Brown, Wei-Ting Hwang, Deborah K. Armstrong, Stephanie Gaillard, Robert Giuntoli, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2800–2807.
https://doi.org/10.1158/1078-0432.CCR-22-2444
Published: 01 August 2023
View article titled, C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Open the PDF for C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A11: Generation and characterization of immune-competent syngeneic model of muscle-invasive bladder cancer (MIBC)

Free
Shruti D. Shah, Bryan Gillard, Ellen Karasik, Michelle Wrobel, Michael T. Moser, Barbara A. Foster
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15_Supplement): A11.
https://doi.org/10.1158/1557-3265.BLADDER19-A11
Published: 03 August 2020
View article titled, Abstract A11: Generation and characterization of immune-competent syngeneic model of muscle-invasive bladder cancer (MIBC)
Journal Articles

Abstract A72: Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer

Free
Payal D. Shah, Haley Zarrin, Stephanie Wethington, Nawar Latif, Lainie Martin, Diego Rodriguez, Katie Elkins, Robert Giuntoli, Robert Burger, Janos Tanyi, Mark Morgan, Susan M. Domchek, Stephanie Gailliard, Deborah K. Armstrong, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A72.
https://doi.org/10.1158/1557-3265.OVCA19-A72
Published: 01 July 2020
View article titled, Abstract A72: Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer
Journal Articles

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

Available to Purchase
Kendra Sweet, Rami Komrokji, Eric Padron, Christopher L. Cubitt, Joel G. Turner, Junmin Zhou, Alan F. List, David A. Sallman, Jana L. Dawson, Daniel M. Sullivan, Julio Chavez, Bijal D. Shah, Jeffrey E. Lancet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 54–60.
https://doi.org/10.1158/1078-0432.CCR-19-2169
Published: 03 January 2020
View article titled, Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Open the PDF for Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation

Free
Xin Shelley Wang, Qiuling Shi, Nina D. Shah, Cobi J. Heijnen, Evan N. Cohen, James M. Reuben, Robert Z. Orlowski, Muzaffar H. Qazilbash, Valen E. Johnson, Loretta A. Williams, Tito R. Mendoza, Charles S. Cleeland
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (5): 1366–1374.
https://doi.org/10.1158/1078-0432.CCR-13-2442
Published: 02 March 2014
View article titled, Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation
Open the PDF for Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation in another window
Journal Articles

Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.

Free
S H Bernstein, J P Fay, N P Christiansen, L Pinero, D Shah, M Stephan, G P Herzig
Journal: Clinical Cancer Research
Clin Cancer Res (1997) 3 (9): 1519–1526.
Published: 01 September 1997
View article titled, Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Open the PDF for Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. in another window